SYSTEMATIC REVIEW

ESPNIC clinical practice guidelines: intravenous maintenance fluid therapy in acute and critically ill children— a systematic review and meta-analysis

David W. Brossier1, Lyvonne N. Tume2, Anais R. Briant3, Corinne Jotterand Chaparro4,5, Clémence Moullet4, Shancy Rooze6, Sascha C. A. T. Verbruggen7, Luise V. Marino8, Fahad Alsohime9, Sophie Beldjilali10, Fabrizio Chiusolo11, Leonardo Costa12, Capucine Didier13, Stavroula Ilia14, Nyandat L. Joram15, Martin C. J. Kneyber16, Eva Kühlwein17, Jorge Lopez18, Jesus López-Herce18, Huw F. Mayberry19, Fortesa Mehmeti20, Magdalena Mierzewska-Schmidt21, Maria Miñambres Rodríguez22, Claire Morice20, John V. Pappachen22, Florence Porcheret24, Leonor Reis Boto25, Luregn J. Schlapbach26, Hakan Tekguc27, Konstantinos Tziouvas28, Jean-Jacques Parienti29, Isabelle Goyer30, and Frederic V. Valla13,31* on behalf of the Metabolism Endocrinology and Nutrition section of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC)

© 2022 The Author(s), corrected publication 2023

Abstract

Purpose: Intravenous maintenance fluid therapy (IV-MFT) prescribing in acute and critically ill children is very variable among pediatric health care professionals. In order to provide up to date IV-MFT guidelines, the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) undertook a systematic review to answer the following five main questions about IV-MFT: (i) the indications for use (ii) the role of isotonic fluid (iii) the role of balanced solutions (iv) IV fluid composition (calcium, magnesium, potassium, glucose and micronutrients) and v) the optimal amount of fluid.

Methods: A multidisciplinary expert group within ESPNIC conducted this systematic review using the Scottish Intercollegiate Guidelines Network (SIGN) grading method. Five databases were searched for studies that answered these questions, in acute and critically children (from 37 weeks gestational age to 18 years), published until November 2020. The quality of evidence and risk of bias were assessed, and meta-analyses were undertaken when appropriate. A series of recommendations was derived and voted on by the expert group to achieve consensus through two voting rounds.

Results: 56 papers met the inclusion criteria, and 16 recommendations were produced. Outcome reporting was inconsistent among studies. Recommendations generated were based on a heterogeneous level of evidence, but consensus within the expert group was high. “Strong consensus” was reached for 11/16 (69%) and “consensus” for 5/16 (31%) of the recommendations.

*Correspondence: frederic.valla@chu-lyon.fr
31 Service de Réanimation Pédiatrique, Hôpital Femme Mère Enfant, 59 Boulevard Pinel, 69500 Bron, France
Full author information is available at the end of the article
Introduction

Intravenous maintenance fluid therapy (IV-MFT) has been defined as the water and electrolyte prescription designed to replace anticipated physiologic water and electrolyte losses over the ensuing 24-h period [1]. Maintenance fluid therapy is provided by enteral hydration and/or IV-MFT which comprises both specific IV-MFT prescription, but also additional fluids administered as vectors of various treatments, blood products, or line flush infusions. IV-MFT should be differentiated from fluid boluses and resuscitation fluids that are administered to correct a relative or true fluid deficit, or from replacement fluids that are administered to correct abnormal fluid losses, even if this might be challenging as they are often administered simultaneously. IV-MFT is a standard of care for many hospitalized children in both acute and critical care settings (i.e. emergency department, pediatric wards, surgical wards or intermediate (high dependency) care units and pediatric intensive care units (PICU)). Despite this, maintenance fluid prescribing practices vary considerably [2] and guidelines are scarce [3]. Historically, IV-MFT prescriptions (fluid volume calculation formulas and solution composition) were based on Holliday and Segar’s work [4]. Since then, the use of these guidelines has been associated with potentially severe complications such as hyponatremia, fluid overload and hyperchloremic acidosis, due to inappropriate fluid composition and/or infusion rates/volumes [3, 5–7]. Several established practices are currently questioned. First, the ideal fluid tonicity, i.e. the osmotic pressure gradient of the fluid which is determined by the concentration of osmotic or non-penetrating solutes, mainly sodium [8]. Second, the chloride content and balanced nature of the fluid (i.e. balanced or buffered solutions are produced after the replacement of part of the chloride anions by organic anions to align to the plasma chloride levels, which may impact on acid–base equilibrium). Finally, the volume of fluid administered, especially in situations where patients are at risk of increased anti-diuretic hormone (ADH) secretion and free water excretion impairment [7]. Over the past decade, several pediatric societies have developed guidelines and recommendations surrounding IV-MFT, but their impact has been limited by a lack of dissemination, a lack of recent systematic reviews and because some important questions remained unanswered [3, 9, 10]. In 2020, the Metabolism, Endocrine and Nutrition (MEN) section of the European Society of Pediatric and Neonatal Intensive care (ESPNIC) formed a working group to develop European guidelines on IV-MFT. These guidelines aim to provide evidence-based recommendations around the indications for IV-MFT, the tonicity of IV-MFT, the electrolyte or glucose content and the volume of IV-MFT administered to children from term to 18 years of age.

Method

To generate these evidence-based guidelines, we followed the Scottish Intercollegiate Guidelines Network (SIGN) 50 methodology [11, 12] and results are presented in line with the EQUATOR PRISMA checklist for systematic reviews [13] and the AGREE guideline reporting checklist [14]. The systematic review was registered on PROSPERO on December 15, 2020, when the research protocol was finalized by the working group (CRD42020218847) [15].

Selection of members

In September 2020, under ESPNIC, three project leaders (DB, LT and FVV) formed a working group of members within the MEN section. This group comprised medical doctors, nurses, pharmacists and dieters, and was created following a call for interested candidates. Selection by the project leaders was based on expertise in the methods and experience in the field of pediatric acute and intensive care, metabolism, and research. This work group also included an academic librarian specialized in systematic reviews, a systematic review methodology, an epidemiologist and a biostatistician specialized in meta-analyses. There was no industry input into the guidelines development. No member of the working group received honoraria for any role in the process and all members have declared any potential conflicts of interest.

Conclusions: Key recommendations are to use isotonic balanced solutions providing glucose to restrict IV-MFT infusion volumes in most hospitalized children and to regularly monitor plasma electrolyte levels, serum glucose and fluid balance.

Keywords: Isotonic fluids, Balanced fluids, Hyponatremia, Fluid balance, Intensive care, Acutely ill children

Take-home message

A systematic review was conducted to produce guidelines on intravenous maintenance fluid therapy in acutely and critically ill children. Sixteen recommendations were produced, which suggest favouring isotonic balanced glucose-containing fluids designed for children, and to infuse them in lower amounts than Holliday and Segar’s formula.
Question development
The content and wording of the clinical questions was agreed at the first online meeting. All questions were structured in the Population, Intervention, Control, and Outcome(s) (PICO) format as follows:

**Population:** acute and critically ill children aged term to 18 years. Critically ill children are those presenting with severe organ failure(s) or requiring pediatric intensive care admission; acutely ill children are those presenting with an acute non-critical condition and requiring in hospital care (e.g. admitted to the emergency department, to pediatric wards, intermediate or high dependency units, or post-surgery). Preterm babies (<37 weeks gestational age) and the intra-operative setting were outside the scope of the guidelines.

The agreed questions were as follows:

1. **PICO1—Indication:** Does IV-MFT versus other hydration therapies (none, oral or enteral route) impact on clinical outcomes?
2. **PICO2—Tonicity:** Do isotonic solutions versus hypotonic solutions (as IV-MFT) impact on clinical outcomes?
3. **PICO3—Balanced fluids:** Do balanced solutions versus non-balanced solutions (as IV-MFT) impact on clinical outcomes?
4. **PICO4—Composition:** Does the composition of IV-MFT in terms of glucose, electrolytes (P, Mg, Ca, K), vitamins and trace elements impact on clinical outcomes?
5. **PICO5—Amounts:** Does the use of a restrictive IV-MFT volume versus the standard Holliday and Segar calculated volume impact on clinical outcomes?

**Outcomes:** Standard outcomes (i.e. mortality and length of hospital or PICU stay) were selected. PICO specific outcomes were further identified: hypo or hypernatremia for PICO 2; hyper-chloremia and acidosis for PICO 3; hypo or hyper-glycemia, -kalemia, -phosphoremia and -magnesemia for PICO 4; fluid balance for PICO 5. However, the preliminary search revealed a large inconsistency in outcome reporting among studies and among PICOs, with discrepancy between outcome definition, presentation, and time of assessment. Consequently, all reported outcomes in reviewed studies were extracted and later included in meta-analysis whenever possible.

Each member of the working group was allocated to a sub-group dedicated to one of the five PICO questions. Allocation of the members to these subgroups was decided by the project leaders according to each member’s preferences and expertise, ensuring a balanced distribution by countries, between professional disciplines, between junior and senior clinicians and between researchers. In each of the five subgroups, group leaders were allocated based on their methodological experience in conducting previous systematic reviews and guideline development.

Literature search and inclusion criteria
After an initial scoping search, each group identified MESH terms for their PICO questions. Subsequently, the medical librarian undertook the literature search on five databases (PubMed/Medline; Web of Science; Scopus; Cochrane; Embase) for each PICO question. The inclusion criteria for papers were as follows: (1) all papers published until November 2020; (2) written in English, French, Spanish or German with an English abstract; (3) inclusion of critically ill or acutely ill (in the hospital setting) children aged from 37 weeks’ gestational age (GA) to 18 years of age; (4) study designs were randomized controlled trials, cohort studies, before and after studies and case/control studies. To ensure an exhaustive search, literature reviews and editorials were sought and their reference lists checked, but they were not included in the data extraction. Animal studies, case studies, conference abstracts and letters were excluded. The search equations for each PICO question are presented in Supplementary Material 1.

After the removal of duplicates, the librarian uploaded the paper abstract for each PICO question, into the review online software Rayyan [Rayyan Systems Inc. Cambridge, Mass, USA], which access was shared with all the members of the working group.

Selection of relevant studies
Using Rayyan software, each PICO group was responsible for screening for relevance, by title and abstract, the articles for their PICO search, as per the inclusion criteria. At least, two group members, blinded to each other, performed this screening, to reduce subjectivity. In the case of disagreement, differences in decision were resolved via a discussion. If it could not be resolved, a third member was involved. Once all relevant papers were agreed, the full text papers were retrieved by the librarian and shared with each PICO group. A similar screening process was applied to full text manuscripts (double blind screening,) based on inclusion/exclusion criteria, until a final list of papers was agreed for data extraction.

Data extraction and assessment of methodological quality
Once papers were agreed for inclusion for each PICO, papers were independently analyzed by two group members (excluding any authors of the paper). Each member extracted key data and summarized the main findings in a standardized data extraction form, according to the study design. Concurrently the same two reviewers assessed the risk of bias according to the Cochrane risk-of-bias tool for randomized trials [16] and to the Newcastle–Ottawa Quality Assessment Form for cohort studies [17].
In case of disagreement, differences in assessment were resolved via discussion, involving the group leader(s) if required.

**Data analysis**

When appropriate, data were combined statistically in a meta-analysis. To be combined the data had to meet the following criteria: (1) more than one study; (2) the combined studies were of one study design either randomized trials or observational studies; (3) the population and the intervention were sufficiently similar; (4) the outcomes were the same, or for continuous outcome variables, data on the distribution of the variable was available; (5) the risk of bias was not considered critical according to the SIGN grading system. If two or more groups of patients in a same study were independent, we analyzed each sample as an independent study. Two biostatisticians (AB, JJP) conducted the meta-analyses, but did not participate in development of the recommendations or the voting process.

To compare experimental and control groups of randomised controlled trials (RCTs), we calculated the effect sizes and their 95% confidence intervals using the mean difference for quantitative endpoints and odds ratio for qualitative endpoints, weighted by the inverse of the variance. The analyses were performed using a random effects model. The heterogeneity of outcomes was determined using chi-squared and Higgins $I^2$ tests: a $p$-value < 0.05 or an $I^2 \geq 50\%$ indicated significant heterogeneity. If the heterogeneity was significant and the conditions for the validity of the analysis were verified, a sensitivity analysis was performed to assess the robustness of the results, excluding the most influential studies. The publication bias was explored for meta-analyses with four or more included studies using the funnel plots.

A $p$ value less than 0.05 was considered significant; all $p$ values were two-tailed. Meta-analyses were performed using Review Manager software (RevMan, Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

**Consensus methodology, grading of the recommendations and voting rounds**

Two online consensus meetings took place in October and November 2021. At these meetings, each group presented their conclusions based on the results from the systematic review and the meta-analyses. A first draft of recommendations was proposed to the whole study team. The wording of the recommendations was discussed with the study team and reworded if required. The classification of the grades of recommendation (A–D, Good Clinical Practice) was undertaken according to the SIGN grading system [11] (supplemental material 2). After those meetings, the recommendations, the supporting rationales, and the recording of the meetings were made available online to the whole team before the online voting. Every member of the study team attended the meetings or watched the meeting recordings and read the proposed rational before voting.

In December 2021, all the PICO recommendations were combined in an online survey (Survey Monkey, Inc. (Palo Alto, CA)) for the members to vote, the intention being to gain consensus using a modified Delphi method [18]. Members were required to indicate “agreement”, “partial agreement with a suggested minor wording change” or “disagreement, with free comments” for each recommendation.

Consensus was defined as “strong consensus” (> 95%), as “consensus” (75–95%) and “no consensus” (< 75%) agreement. In the case of less than 95% agreement during the first online voting, each PICO group was asked to modify the wording of the recommendation according to members suggestions or, if they chose to make no amendment, to provide an explanation. A second and final online voting round took place in January 2022 to attempt to reach strong consensus on the set of recommendations. Members were required to indicate “agreement” or “disagreement”, with explanations and proposal.

**Results**

A total of 18,399 abstracts were screened (Fig. 1 PRISMA flow chart). Subsequently 56 publications from 1969 to 2021 were included [19–74] for data extraction, which included 11,689 patients in both acute and critical care, medical and surgical care settings and used in the development of 16 recommendations (Table 1).

Overall, the level of evidence was low [11] with most studies graded 1 or lower with a serious risk of bias (Table 2 and supplemental files 3–6).

Furthermore, the data were only suitable to combine in a meta-analysis (Figs. 2–5) for some outcomes in four of the PICO questions (PICO 4 on composition did not allow for any meta-analysis). However, outcomes varied significantly between studies and limited the scope of the meta-analysis. All forest plots are available in Supplement files 3, 4, 5 and 6 with the respective heterogeneity assessment and relative risks.

Table 2 provides the list of included studies and their main characteristics; Table 3 summarizes for each PICO the profile of the patients recruited in these studies.

For PICO 1 on indications for IV-MFT, a meta-analysis included 1668 children. It showed no significant difference in length of stay between enteral and parenteral hydration (mean difference $= 9.09$, 95% CI $[-1.24–19.43]$, $p = 0.08$) (Fig. 2) but a trend towards a reduction
in length of hospital stay in the enteral group [23, 24, 27, 28].

For PICO 2 on isotonic IV-MFT solutions, a meta-analysis of 17 RCTs (involving 3356 patients) assessing the risk of developing hyponatremia showed that isotonic solutions significantly reduced this risk compared with hypotonic fluids, with an odds ratio of 0.41 (95% CI [0.26–0.67], \( p = 0.0003 \)), although the heterogeneity was high between studies [31–34, 36–40, 42, 45, 46] (Fig. 3).

In PICO 3 on balanced IV-MFT solutions, the length of acute care or PICU stay were slightly but significantly decreased in children receiving balanced solutions in a meta-analysis of 5 studies, including 283 patients (mean difference: \(-0.20 \text{ days}; 95\% \text{ CI } [-0.33; -0.08], p = 0.001 \) [57, 58, 61–63] (Fig. 4).

For PICO 4, the data did not allow the conduct of any meta-analysis.

In PICO 5 on the amount of IV-MFT, a restrictive strategy was significantly associated with a lower change in plasma sodium (mean difference \(=\) 1.95; 95% CI [0.29; 3.62], \( p = 0.02 \)) after 12 h or more of treatment, in a meta-analysis pooling 167 patients in six subgroups in three RCTs, including patients in the PICU [71, 73, 74] (Fig. 5).

Figure 6 provides a short answer to each PICO question.

The grading of the 16 recommendations was heterogeneous (ranging from good clinical practice and expert opinion to Grade A), according to the SIGN grading [11] and the quality of the meta-analysis (Table 1). After the 2-round voting process, strong consensus (> 95% agreement) was reached for 11/16 (69%) and consensus (90% < agreement < 95%) for 5/16 (31%) of the recommendations.

A long rationale supporting each recommendation is provided for each PICO question in supplemental files 7–11. This details the underlying background and pathophysiology of the PICO question, summarizes current European practice [2], discusses available recommendations in adults or other pediatric settings, provides further details of our literature search, data extraction and analysis of the data, analyzes the volume of evidence, its applicability, generalizability, consistency and clinical impact of the recommendations and finally provides the recommendation.

Discussion

Summary of findings

These ESPNIC evidence-based recommendations provide guidance for clinicians using IV-MFT in children both in acute hospital and intensive care settings. They are based on a comprehensive literature search, including literature up to November 2020.

We were able to propose 16 recommendations corresponding to our questions with a high level of consensus, and to provide an extensive rationale to support each of them, available in supplemental material. Unfortunately, the general level of evidence remains low, both in terms of quantity and quality. Few well conducted and low risk of bias RCTs were available. Furthermore, the study populations, settings and interventions were heterogeneous and, in many cases, made it difficult to pool and to
Thus, even with a strong consensus, the majority of the recommendations 12/16 (75%) might be considered as weak (C or under) as they are based on a low level of evidence.

Consistency with other guidelines and recent publications
Our recommendations are consistent with the 2018 American Academy of Pediatrics clinical practice IV-MFT guidelines regarding the use of isotonic fluids [3]. Indeed, the American Academy of Pediatrics

| Recommendations | Level of evidence | Consensus |
|-----------------|------------------|-----------|
| **PICO 1: IV-MFT indications** | | |
| In acutely ill children, the enteral or oral route for the delivery of maintenance fluid therapy should be considered, if tolerated, to reduce the failure rate of hydration access and costs | C | Strong consensus |
| In critically ill children with improving hemodynamic state, the enteral or oral route for the delivery of maintenance fluid therapy should be considered, if tolerated, to reduce length of stay in term neonates | GCP | Strong consensus |
| **PICO 2: use of isotonic fluids** | | |
| In acutely and critically ill children, isotonic maintenance fluid should be used to reduce the risk of hyponatremia | A | Strong consensus |
| **PICO 3: use of balanced solutions** | | |
| In acutely and critically ill children, balanced solutions should be favoured when prescribing intravenous maintenance fluid therapy to slightly reduce length of stay | B | Strong consensus |
| In acutely and critically ill children, balanced solutions should be used when prescribing intravenous maintenance fluid therapy to slightly reduce length of stay | A | Strong consensus |
| In acutely and critically ill children, lactate buffer solution should not be considered in the case of severe liver dysfunction to avoid lactic acidosis | D | Consensus |
| **PICO 4: IV-MFT fluid composition (Ca, Mg, P, Micronutrients, Glucose)** | | |
| In acutely and critically ill children, glucose provision in intravenous maintenance fluid therapy should be considered in sufficient amount and guided by blood glucose monitoring (at least daily) to prevent hypoglycaemia | GCP | Consensus |
| In acutely and critically ill children, glucose provision in intravenous maintenance fluid therapy should not be excessive and guided by blood glucose monitoring (at least daily) to prevent hyperglycaemia | B | Consensus |
| In acutely and critically ill children, there is insufficient evidence to recommend routine supplementation of magnesium, calcium and phosphate in intravenous maintenance fluid therapy | GCP | Strong consensus |
| In acutely and critically ill children, an appropriate amount of potassium should be considered and added to intravenous maintenance fluid therapy, based on the child's clinical status and regular potassium level monitoring to avoid hypokalemia | GCP | Consensus |
| In acutely and critically ill children, there is insufficient evidence to recommend routine supplementation of vitamins and trace elements in intravenous maintenance fluid therapy, in the absence of signs of deficiency | GCP | Strong consensus |
| **PICO 5: volume of IV-MFT administered** | | |
| In acutely and critically ill children, in order to prevent fluid creep and reduce fluid intake, the total daily amount of maintenance fluid therapy should be considered including: IV fluids, blood products, all IV medications (both infusions and bolus drugs), arterial and venous line flush solutions and enteral intake, but does not include replacement fluids and massive transfusion | D | Strong consensus |
| In acutely and critically ill children, avoidance of fluid overload and cumulative positive fluid balance should be considered, to avoid prolonged mechanical ventilation and length of stay | D | Strong consensus |
| In acutely and critically ill children, who are at risk of increased endogenous secretion of ADH, restriction of total intravenous maintenance fluid therapy volume (calculated by Holliday and Segar formula) should be considered to some extent, to avoid a decrease in natremia but the amount and duration of this restriction is uncertain | C | Strong consensus |
| In acutely and critically ill children who are at risk of increased endogenous secretion of ADH, restricting maintenance fluid therapy volume to between 65–80% of the volume calculated with the Holliday and Segar formula should be considered to avoid fluid overload | GCP | Strong consensus |
| In children at greater risk of oedematous states, e.g., heart failure, renal failure or hepatic failure, restricting maintenance fluid therapy volume to between 50% to 60% of the volume calculated with the Holliday and Segar formula should be considered to avoid fluid overload | GCP | Strong consensus |
| Whilst receiving intravenous maintenance fluid therapy, re-assessment of acutely and critically ill children should be considered at least daily in terms of fluid balance and clinical status and regularly regarding electrolytes, especially sodium level | D | Consensus |

ADH anti-diuretic hormone; GCP good clinical practice; IV-MFT intravenous maintenance fluid therapy; Consensus (expert votes): 90% < agreement < 95%; Strong consensus: ≥ 95% agreement

Long rationales are available for each recommendation in supplemental materials 7–11
guidelines strongly recommended the use of isotonic fluids in children between 28 days to 18 years of age in acute or intensive care settings. However, our guidelines extend beyond the American guidelines as they also make recommendations on the indications for IV-MFT, on the composition of IV-MFT, and on the amount of IV-MFT that should be prescribed. In 2021, Leung and colleagues [75] published a consensus statement on IV-MFT in hospitalized children, based on a review of the literature (2000–2019). Their recommendations are similar to ours regarding prioritization of the enteral route, the use of isotonic fluids, the reduced amount of fluids administered and the type of monitoring. With the exception of isotonic fluids (strong recommendation with high quality of evidence), recommendations were all consensus based on low-quality evidence and expert opinion. The use of balanced fluids was not addressed.

Our study protocol included literature until November 2020 only; we used the same search equations and inclusion criteria to extract recent IV-MFT studies (December 2020–June 2022) to ensure the consistency of their findings with our guidelines. Twenty-one new studies (and 3 ongoing trials) were identified and are summarized in supplemental digital content 12. Their findings are globally consistent with our recommendations, especially regarding the use of isotonic fluids, reduced infusion volumes and the use of the enteral route when possible. The impact of isotonic fluids has now been studied in specific sub-groups of children such as newborns and patients with diabetic ketoacidosis. Balanced solutions are currently being studied, and we have identified three ongoing RCTs comparing them to non-balanced solutions which may help revising our guidelines or adapting their level of evidence in the future.

Implications for practice
The reporting of key outcomes was inconsistent within studies, which prevented us from conducting other meta-analyses. For example, the impact of isotonic and/or balanced solutions on Na and Cl plasma levels was presented as absolute values in some papers, or changes over time, or absolute difference in others. Improving the standardization of outcome reporting in future trials is essential to allow pooling of the data. In the future, our expert group aims to conduct an international Delphi study to gain expert consensus and develop a core outcome set to be reported in future studies on IV-MFT in children. Despite this, these guidelines highlight several important points that must be considered in daily practice when prescribing IV-MFT for children. First, the intravenous route for hydration is not required in every clinical situation. Second, isotonic IV-MFT should be preferred over hypo or hypertonic solutions. Third, balanced fluids should be the standard IV-MFT solution used in children. Fourth, the IV fluid composition is important, and glucose and plasma electrolyte monitoring is essential. Finally, the harm of excessive fluids and volume overload is highlighted, and the daily calculation of fluid balance is essential for any child receiving IV-MFT.

Future implementation challenges
As per its definition, IV-MFT needs to be differentiated from IV replacement therapy, which aims to compensate for abnormal losses (e.g. skin losses in case of major wounds or burns, intestinal losses in case of severe enteropathy, losses through drains, etc.). However, IV-MFT and replacement fluids may be administered through single IV fluid prescription which then needs to combine both IV-MFT recommendations (in terms of amounts and composition) and adapt to the rate of loss and composition of fluid losses. The implementation of these recommendations into clinical practice may be challenged by the lack of availability of ready-to-use solutions adapted for children in some European countries. A recent survey by Morice et al. [2] reported some centers having to reconstitute isotonic glucose IV-MFT solutions within clinical care units. The use of ready-to-use IV-MFT is beneficial to avoid reconstitution errors, physico-chemical stability issues and microbiological contaminations. Furthermore, products designed for adults do not usually provide glucose and, therefore, do not meet the requirements of younger children. Perioperative maintenance fluids designed as per Sümpelmann et al. recommendations [10] (Glucose 1–2.5%) may not provide sufficient amounts of glucose if used outside the perioperative setting. Isotonic balanced solutions, providing some glucose (4 to 10%) and limited amounts of potassium (+/- 4 mmol/L), would meet most children’s requirements in terms of IV-MFT. Solutions such as these can be found in certain countries in various amounts (250, 500 and 1000 mL bags) and have an osmolarity compatible with peripheral infusion. Nevertheless, such solutions are inconsistently available through Europe. Availability of ready-to-use IV-MFT solutions that are tailored to childrens needs would help facilitate the implementation of these new ESPNIC recommendations.

Limitations
The main limitation of these evidence-based recommendations is the general paucity of evidence and the low level of evidence around some of the questions. We have included all studies published until 2021 due to the paucity of studies available, but most (80.0%) were published
Table 2 Summary table of studies included to produce recommendations and their SIGN level of evidence

| Study: author and year of publication | Study examined | Study design settings and location | Patient population | Summary of results | Risk of bias | Applicability to our question/patients | SIGN level of evidence |
|--------------------------------------|----------------|-----------------------------------|--------------------|--------------------|-------------|----------------------------------------|-----------------------|
| Mackenzie et al. (1991)              | PICO 1 IV vs enteral hydration with electrolyte solutions | RCT Single centre Australia | 104 dehydrated acutely ill children with gastroenteritis | No difference | Serious risk | High | 1 — |
| Nager et al. (2002)                  | PICO 1 IV vs enteral hydration with electrolyte solutions | RCT Single Centre United States of America (USA) | 90 dehydrated acutely ill children with gastroenteritis | Higher costs in IV group | Serious risk | High | 1 — |
| Sharifi et al. (1985)                | PICO 1 IV rehydration vs enteral rehydration | RCT Single Centre Iran | 470 dehydrated acutely ill children with gastroenteritis | Less hyponatremia, acidosis hypokalaemia, diarrhoea, and higher weight gain in enteral group | Serious risk | High | 1 — |
| Spandorfer et al. (2005)             | PICO 1 IV rehydration vs enteral rehydration | RCT Single Centre USA | 73 dehydrated acutely ill children with gastroenteritis | No difference | Serious risk | Moderate | 1 — |
| Rao et al. (2020)                    | PICO 1 IV hydration vs enteral feeding | RCT Single Centre India | 186 Critically ill term neonates on inotropes | No difference | Low risk | High | 1 + + |
| Oakley et al. (2013)                 | PICO 1 IV vs enteral hydration or enteral feeds | RCT Multicentre Australia and New Zealand | 759 acutely ill bronchiolitis children | No difference | Serious risk | High | 1 — |
| Oakley et al. (2017)                 | PICO 1 IV vs enteral hydration or enteral feeds | RCT Multicentre Australia and New Zealand | 759 acutely ill bronchiolitis children | Higher costs in IV group | Serious risk | High | 1 — |
| Duke et al. (2002)                   | PICO 1 100% 0.45%NaCl-GS IV vs 60% breast milk | RCT Multicentre Papua New Guinea | 357 acutely ill children with meningitis | Improved outcomes in IV hydration group | Serious risk | Moderate | 1 — |
| Saeidi et al. (2009)                 | PICO 1 Breast milk+IV hydration, vs breast milk | RCT Single Centre Iran | 100 term neonates requiring phototherapy for hyper-bilirubinemia | Bilirubin levels decreased faster in the IV group | Serious risk | Moderate | 1 — |
| Wilson et al. (1990)                 | PICO 1 IV vs no IV hydration | RCT Single Centre United Kingdom | 50 children undergoing tonsillectomy | No difference | Serious risk | High | 1 — |
| Easa et al. (2013)                   | PICO 1 EN feeds with supplemental IV hydration, vs EN feeds or EN hydration | RCT Single Centre Iraq | 64 term neonates requiring phototherapy for hyper-bilirubinemia | No difference | Serious risk | Moderate | 1 — |
| Szabo et al. (2015)                  | PICO 1 NPO+low IV hydration, Vs NPO+high IV hydration, Vs PO+low IV hydration, Vs PO+high IV hydration | Retrospective cohort study Single Centre USA | 201 acutely and critically ill children with pancreatitis | Improved outcomes in the PO+high IV hydration group | Good quality | Moderate | 2 + |
| Study: author and year of publication | Study examined | Study design and location | Patient population | Summary of results | Risk of bias | Applicability to our question/patients | SIGN level of evidence |
|--------------------------------------|----------------|--------------------------|-------------------|-------------------|------------|---------------------------------------|---------------------|
| McNab et al. (2015)                  | PICO 2 Isotonic (Plasmalyte-G5%®) vs Hypotonic (G5%-NaCl 0.45%) | RCT Single Centre Australia | 641 acutely ill children | Lower risk of hyponatremia in isotonic group | Serious risk | Moderate | 1— |
| Lehtiranta et al. (2021)             | PICO 2 Isotonic (Plasmalyte-G5%®) vs Hypotonic (G5%-NaCl 80 mmol/L) | RCT Single Centre Finland | 614 acutely ill children | No significant difference in natremia | Serious risk | Moderate | 1— |
| Coulthard et al. (2012)              | PICO 2 and PICO 3 and PICO 5 Hartmann-G5% full maintenance vs 0.45%NaCl-G5%, 2/3 of Holliday and Segar formula | RCT Single Centre Australia | 82 critically ill children after neurosurgery | smaller postoperative fall in plasma sodium in Hartmann-G5% group No difference in Cl and HCO3 plasma levels No data support the effect of rate/amount due to mixed intervention | Serious risk | Low | 1— |
| Almeida et al. (2015)                | PICO 2 Isotonic (0.9%NaCl) vs hypotonic (0.45%NaCl) IV-MFT | RCT Single Centre Portugal | 233 critically ill children | Lower risk of hypernatremia with 0.9% saline than hyponatremia with 0.45% | Serious risk | Moderate | 1— |
| Bagri et al. (2019)                  | PICO 2 Isotonic (0.9%NaCl) vs hypotonic (0.45%NaCl) IV-MFT | RCT Single Centre India | 150 acutely ill children | lower serum osmolality at 48 h in the hypotonic group | Serious risk | High | 1— |
| Castilla et al. (2019)               | PICO 2 Isotonic (0.9%NaCl) vs hypotonic (0.3%NaCl) IV-MFT | RCT Single Centre Spain | 130 critically ill children after surgery | Lower risk of hyponatremia in isotonic group | Serious risk | High | 1— |
| Choong et al. (2011)                 | PICO 2 Isotonic (0.9%NaCl) vs hypotonic (0.45%NaCl) IV-MFT | RCT Single Centre Canada | 258 acutely and critically ill children after surgery | Lower risk of hyponatremia in isotonic group | Low risk | High | 1+ + |
| Flores et al. (2016)                 | PICO 2 Isotonic (G5%-NaCl 0.9%) vs Hypotonic (G5%-NaCl 0.45%) vs Hypotonic (G5%-NaCl 0.3%) | RCT Single Centre Mexico | 163 acutely ill children | Lower risk of hyponatremia in isotonic group | Low risk | Moderate | 1+ |
| Friedman et al. (2015)               | PICO 2 Isotonic (G5%-NaCl 0.9%) vs Hypotonic (G5%-NaCl 0.45%) vs Hypotonic (G5%-NaCl 0.18%) lower infusion rate | RCT Single Centre Canada | 110 acutely ill children with acute respiratory diagnosis | No significant differences | Low risk | High | 1+ |
| Kannan et al. (2010)                 | PICO 2 & PICO 5 Isotonic (G5%-NaCl 0.9%) vs Hypotonic (G5%-NaCl 0.18%) vs Hypotonic (G5%-NaCl 0.18%) lower infusion rate | RCT Single Centre India | 167 acutely ill children | Less hyponatremia in isotonic group Less hyponatremia in the restrictive group | Moderate risk (serious) | High (moderate) | 1+ (1—) |
| Study, author and year of publication | Study examined | Study design and location | Patient population | Summary of results | Risk of bias | Applicability to our question/patients | SIGN level of evidence |
|--------------------------------------|----------------|--------------------------|--------------------|-------------------|-------------|--------------------------------------|----------------------|
| Kumar et al. (2020)                  | PICO 2 Isotonic (G5% NaCl 0.9%) vs Hypotonic (G5%- NaCl 0.45%) | RCT Single Centre India | 168 acutely ill children | No difference | Moderate risk | Moderate | 1 | |
| Montanana et al. (2008)              | PICO 2 Isotonic (NaCl 140 mmol/L) vs Hypotonic (20–100 mmol/L Na) | RCT Single Centre Spain | 122 critically ill children | Increased risk of hyponatremia in hypotonic group | Serious risk | High | 1 | |
| Pemde et al. (2015)                  | PICO 2 Isotonic (NaCl 0.9%) vs Hypotonic (G5%- NaCl 0.45%) | RCT Single Centre India | 92 acutely ill children with central nervous system infection | Less Hyponatremia in the isotonic group | Serious risk | Low | 1 | |
| Ramanathan et al. (2016)             | PICO 2 Isotonic (NaCl 0.9%) vs Hypotonic (NaCl 0.18%) | RCT Single Centre India | 119 acutely ill children with pneumonia | Increased risk of hyponatremia in hypotonic group | Serious risk | Moderate | 1 | |
| Rey et al. (2011)                    | PICO 2 Isotonic (NaCl 156 mmol/L) vs Hypotonic (50–70 mmol/L Na) | RCT Multicentre Spain | 125 critically ill children | Increased risk of hyponatremia in hypotonic group | Serious risk | Low | 1 | |
| Saba et al. (2011)                   | PICO 2 Isotonic (G5%-NaCl 0.9%) vs Hypotonic (G5%-NaCl 0.45%) | RCT Single Centre Canada | 37 acutely ill children requiring IV-MFT | No difference | Serious risk | Moderate | 1 | |
| Torres et al. (2019)                 | PICO 2 Isotonic (G5%-NaCl 0.9%) vs Hypotonic (G5%-NaCl 0.45%) | RCT Single Centre Argentina | 294 acutely and critically ill children requiring IV-MFT | Increased risk of hyponatremia in hypotonic group | Serious risk | Low | 1 | |
| Jorro Baron et al. (2013)            | PICO 2 Isotonic (NaCl 154 mmol/L) vs Hypotonic (77 mmol/L Na) | RCT Single Centre Argentina | 63 critically ill children | Higher Na Plasma levels in isotonic group | Serious risk | High | 1 | |
| Tuzun et al. (2020)                  | PICO 2 Isotonic (G5%-NaCl 0.9%) vs Hypotonic (G5%-NaCl 0.45%) | RCT Single Centre Turkey | 108 critically ill term neonates | Lower plasma Na Change in isotonic group | Serious risk | Low | 1 | |
| Velasco et al. (2018)                | PICO 2 Isotonic (NaCl 154 mmol/L) vs Hypotonic (51–77 mmol/L Na) | Retrospective cohort Single Centre Spain | 111 critically ill children | Less hyponatremia risk in isotonic group | Good quality | High | 2 | |
| Da Silva Vadalao et al. (2015)       | PICO 2 Isotonic (NaCl 0.9%) vs Hypotonic (NaCl 0.18%) | RCT Single Centre Brazil | 50 acutely ill children after appendicectomy | No difference | Critical risk | Low | 1 | |
| Carandang et al. (2013)              | PICO 2 Isotonic (any type) vs Hypotonic (any type) | Retrospective cohort Single Centre USA | 1048 acutely ill children | Increased risk of hyponatremia in the hypotonic group | Poor quality | Low | 2 | |
| Golshekan et al. (2016)              | PICO 2 Isotonic (G5%‑NaCl 0.9%) vs Hypotonic (G5%- NaCl 0.45%) | RCT Single Centre Iran | 75 acutely ill children | Increased risk of hyponatremia in the hypotonic group | Critical risk | Low | 1 | |
|                                        |                |                          |                    |                   |             |                                      |                      |
| Study: author and year of publication | Study examined | Study design and location | Patient population | Summary of results | Risk of bias | Applicability to our question/patients | SIGN level of evidence |
|--------------------------------------|----------------|--------------------------|--------------------|-------------------|-------------|---------------------------------------|----------------------|
| Karageorgos et al. (2018)            | PICO 2 Isotonic (NaCl 0.9%) vs Hypotonic (Na 0.45%, 0.675% or 0.225%) | Retrospective cohort Multicentre USA | 472 acutely ill children | Increased risk of hyponatremia in the hypotonic group | Poor quality | Moderate | 2+ |
| Lima et al. (2019)                   | PICO 3 Plasma-Lyte A® vs NaCl0.9% | RCT Single Centre Brazil | 53 acute and critically ill children after brain tumour surgery | Higher chloremia in the NaCl group, and lower natremia in the balanced group | Serious risk | High | 1-- |
| Naseem et al. (2020)                 | PICO 3 Ringer Lactate vs NaCl 0.9% | RCT Single Centre India | 70 acutely ill children with dehydration and gastroenteritis | Faster resolution of metabolic acidosis occurs with Ringer lactate | Moderate risk | Moderate | 1-- |
| Mahajan et al. (2012)                | PICO 3 Ringer Lactate vs NaCl 0.9% | RCT Single Centre India | 22 acutely ill children with dehydration and gastroenteritis | No difference | Serious risk | Low | 1-- |
| Kartha et al. (2017)                 | PICO 3 Ringer Lactate vs NaCl 0.9% | RCT Single Centre India | 68 acutely ill children with dehydration and gastroenteritis | Clinical and pH improvement increased in the Ringer lactate group | Low risk | Moderate | 1+ |
| Gutman et al. (1969)                 | PICO 3 Ringer Lactate vs Cholera designed replacement solution (45 mmol/L acetate) | RCT Single Centre Taiwan | 27 acutely ill children with dehydration and gastroenteritis (cholera) | Faster normalisation of HCO₃ in the cholera buffer enriched solution | Serious risk | Moderate | 1-- |
| Farrell et al. (2020)                | PICO 3 Ringer Lactate vs NaCl 0.9% | Retrospective cohort Multicentre USA | 1581 acutely ill children with pancreatitis | Shorter length of stay and lower costs in the Ringer lactate group | Fair quality | Moderate | 2-- |
| Yung et al. (2017)                   | PICO 3 Ringer Lactate vs NaCl 0.9% | RCT Single Centre Australia | 77 acute and critically ill children with moderate and severe diabetic ketoacidosis | No difference | Low risk | Moderate | 1++ |
| Williams et al. (2020)               | PICO 3 Plasma-Lyte A® vs NaCl 0.9% | RCT Single Centre India | 66 acutely and critically ill children with moderate and severe diabetic ketoacidosis | No difference | Low risk | Moderate | 1++ |
| Balamuth et al. (2019)               | PICO 3 Ringer Lactate vs NaCl 0.9% | RCT Single Centre USA | 50 acutely ill children with septic shock | No difference (pilot study) | Serious risk | Low | 1-- |
| Bullon et al. (2019)                 | PICO 3 0.9% NaCl, 0.45% NaCl Vs Ringer lactate | Retrospective cohort Multicentre Canada | 543 critically ill children | Lower risk of Hyperchloremic metabolic acidosis in the ringer lactate group | Good quality | High | 2++ |
| Martinez Cara-peto et al. (2018)     | PICO 4 G3.3% vs G5% MV-MFT | RCT Single Centre Spain | 130 critically ill children after surgery | No difference | Serious risk | Moderate | 1-- |
| Study: author and year of publication | Study examined | Study design | Patient population | Summary of results | Risk of bias | Applicability to our question/patients | SIGN level of evidence |
|--------------------------------------|----------------|--------------|---------------------|--------------------|-------------|----------------------------------------|----------------------|
| De Betue et al. (2012)               | PICO 4 Glucose infusion: 2.5 mg/kg/min vs 5 mg/kg/min | RCT Single Centre The Netherlands | 11 critically ill children after cardiac surgery | Lower glycemia in the 2.5 mg group, without hypoglycemia | Low risk | High | 1+ |
| Verbruggen et al. (2011)             | PICO 4 Glucose infusion: 2.5 mg/kg/min vs 5 mg/kg/min | RCT Single Centre The Netherlands | 8 critically ill children after craniosynostosis surgery | Higher hyperglycemia risk in the 5 mg group | Low risk | High | 1+ |
| Lex et al. (2014)                    | PICO 4 G10% vs G5% MV-MFT | Case control study Single Centre Hungary | 596 critically ill children after cardiac surgery | Hospital length of stay was longer in the 10% group | Fair quality | Moderate | 2− |
| Diaz et al. (2018)                   | PICO 5 100% (standard) vs 50% (pre-emptive) of Holliday Segar formula | Case control study Single Centre Chile | 76 critically ill children with sepsis or ARDS | Fluid overload, ventilation duration, length of stay were significantly lower in pre-emptive group | Poor quality | Moderate | 2− |
| Ingelse et al. (2019)                | PICO 5 85% (standard) vs < 70% (conservative) of Holliday Segar formula | RCT Single Centre The Netherlands | 23 critically ill children respiratory infection on mechanical ventilation | No difference | Critical Risk | High | 1− |
| Yung et al. (2009)                   | PICO 5 100% (standard) vs < 2/3 (conservative) of Holliday Segar formula sub studies based on fluid type: A. Normal saline 0.9% B. 4% Dextrose – 0.18% saline | RCT Single Centre Australia | 50 critically ill children | No difference | Serious risk | Moderate | 1− |
| Raksha et al. (2017)                 | PICO 5 0.18% saline in 5%G at 2/3 standard rate vs 0.9% saline in 5%G at standard IV maintenance rate | RCT Single Centre India | 240 critically ill children | Less hyponatremia and shorter length of ICU stay in isotonic group No data support the effect of rate/amount due to mixed intervention | Serious risk | Low | 1− |
| Neville et al. (2010)                | PICO 5 100% (standard) vs < 50% (conservative) of Holliday Segar formula sub studies based on fluid type: A. 5% dextrose + normal saline 0.9% B. 5% dextrose + half normal saline 0.45% | RCT Single Centre Australia | 62 acutely ill children after surgery | No difference | Serious risk | Moderate | 1− |
in the last decade, which reduces the bias from studies published within a large time period. Our definition of acute and critical illness may slightly differ from the one used in some studies as PICU admission policies vary within institutions. For most of the recommendations, apart from PICO 1, sparse evidence prevented us from translating this to specific pediatric populations or specific clinical situations; sub populations should be further studied in future trials to secure extrapolation of these guidelines to specific groups of patients and for different age ranges. Apart from the trials conducted on IV-MFT during phototherapy, term neonates were rarely analyzed as a specific group or a subgroup in most of the studies, and extrapolation of the results to this specific population should be considered with caution. Cardiac patients were included in some of the study populations and recommendations for PICO 2 and 5 are likely to apply to this specific population. Some studies assessed both IV-MFT and replacement or bolus fluid therapy, as these treatments were administered simultaneously or consequentially over the study period. Consequently, this may have introduced a bias in the interpretation of the results, even if the results were consistent with other studies focusing on IV-MFT. However, a consistent fluid strategy considering resuscitation, replacement and maintenance fluid therapy seems reasonable. Furthermore, due to inconsistencies among the interventions (fluids and volumes used) and outcomes, meta-analyses were not possible to conduct for many questions and heterogeneity between studies may have resulted in some bias. Finally, in these evidence-based recommendations, the PICO questions and consensus voting only reflects the view of our ESPNIC expert group. Service users (acute and critically ill children) and their parents were not involved in the design of the project. Despite these limitations, this is the most up to date and extensive review of IV-MFT in children both in acute and critical care settings.
| PICO 1 | Acutely ill children | Critically ill children | No distinction possible between acute and critically ill children |
|--------|----------------------|------------------------|---------------------------------------------------------------|
| 11 studies | Total: 2268 patients | 1 study | Total: 186 term newborns |
| Gastroenteritis \( n = 737 \) | | | |
| Bronchiolitis \( n = 759 \) | | | |
| Meningitis \( n = 357 \) | | | |
| Newborns with hyperbilirubinemia \( n = 164 \) | | | |
| Post tonsillectomy \( n = 50 \) | | | |
| Pancreatitis \( n = 201 \) | | | |

| PICO 2 | Acutely ill children | Critically ill children | No distinction possible between acute and critically ill children |
|--------|----------------------|------------------------|---------------------------------------------------------------|
| 14 studies | Total: 3444 patients | 10 studies | Total: 1692 patients |
| Respiratory failure \( n = 229 \) | | Surgery \( n = 207 \) | |
| Surgery \( n = 229 \) | | Neurosurgery \( n = 82 \) | |
| Central nervous system infection \( n = 92 \) | | Term neonates \( n = 108 \) | |
| Various diagnosis \( n = 2894 \) | | Various diagnosis \( n = 1295 \) | |

| PICO 3 | Acutely ill children | Critically ill children | No distinction possible between acute and critically ill children |
|--------|----------------------|------------------------|---------------------------------------------------------------|
| 7 studies | Total: 1849 patients | 3 studies | Total: 660 patients |
| Gastroenteritis \( n = 187 \) | | DKA \( n = 35 \) | |
| Pancreatitis \( n = 1581 \) | | Neurosurgery \( n = 82 \) | |
| Sepsis \( n = 50 \) | | Various diagnosis \( n = 543 \) | |
| DKA \( n = 31 \) | | | |

| PICO 4 | Acutely ill children | Critically ill children | No distinction possible between acute and critically ill children |
|--------|----------------------|------------------------|---------------------------------------------------------------|
| 0 | | 4 studies | Total: 745 patients |
| | | Post-surgery \( n = 130 \) | |
| | | Post cardiac surgery \( n = 607 \) | |
| | | Post craniosynostosis \( n = 8 \) | |

| PICO 5 | Acutely ill children | Critically ill children | No distinction possible between acute and critically ill children |
|--------|----------------------|------------------------|---------------------------------------------------------------|
| 3 studies | Total: 279 patients | 5 studies | Total: 471 patients |
| Meningitis \( n = 50 \) | | Neurosurgery \( n = 82 \) | |
| Post-surgery \( n = 62 \) | | Respiratory failure \( n = 23 \) | |
| Various diagnosis \( n = 167 \) | | Various diagnosis \( n = 366 \) | |

DKA diabetic keto acidosis

**Fig. 3** Meta-analysis of studies comparing the impact on hyponatremia occurrence of isotonic versus hypotonic solutions
Conclusions
These evidence-based recommendations provide a 'best-available-evidence' guide for both pediatric and intensive care clinicians around the prescription of IV-MFT. Due to a paucity of robust evidence, the evidence level for most of the recommendations is low, even when strong consensus was reached among the expert group. Thus, many recommendations are based on expert opinion. This review clearly identifies the urgent need and gaps for future research in this field. Each of our PICO questions deserves further robust research, and new RCTs should be conducted specifically to clarify the impact of the use of isotonic solutions or balanced solutions in various age groups (term neonates, infants and older children) and a variety of clinical conditions. The lack of evidence regarding optimal electrolyte compositions (K, P, Mg, Ca) of IV-MFT is striking and so is the need for micronutrient additions in IVMFT. Consistent reporting of relevant outcome is mandatory to enable future metanalysis. ESP-NIC intends to update these guidelines every 5 years, following the same methodology. In the future, our expert group also aims to produce tools to help implement these guidelines into clinical practice and promote auditing and monitoring of their implementation.

Fig. 4 Meta-analysis of studies comparing the impact on acute or critical care stay of balanced versus non-balanced solutions

![Meta-analysis of studies comparing the impact on acute or critical care stay of balanced versus non-balanced solutions](image)

Fig. 5 Meta-analysis of studies comparing the impact on natremia of a restrictive versus a non-restrictive fluid strategy

![Meta-analysis of studies comparing the impact on natremia of a restrictive versus a non-restrictive fluid strategy](image)
Indication: Does IV-MFT versus other hydration therapies (none, oral or enteral route) impact on clinical outcomes?

**PICO1**

No significant difference in length of stay but trend towards a reduction in length of hospital stay in patients receiving enteral fluids

Tonicity: Do isotonic solutions versus hypotonic solutions (as IV-MFT) impact on clinical outcomes?

**PICO2**

Yes, isotonic solutions significantly increase the risk of hyponatremia compared with hypotonic fluids

Balanced fluids: Do balanced solutions versus non-balanced solutions (as IV-MFT) impact on clinical outcomes?

**PICO3**

Yes, the length of acute care or PICU stay were slightly but significantly decreased in children receiving balanced solutions

Composition: Does the composition of IV-MFT in terms of glucose, electrolytes (P, Mg, Ca K), vitamins and trace elements impact on clinical outcomes?

**PICO4**

Not able to be answered in a meta-analysis

Amounts: Does the use of a restrictive IV-MFT volume versus the standard Holliday and Segar calculated volume impact on clinical outcomes?

**PICO5**

Yes, a restrictive strategy was significantly associated with a lower change in plasma sodium

Fig. 6 Short answers to PICO questions

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00134-022-06882-z.

Author details

1 Pediatric Intensive Care, Medical School, Université Caen Normandie, CHU de Caen, Caen, France. 2 Pediatric Intensive Care Unit Alder Hey Children's Hospital, Faculty of Health, Social Care and Medicine, Edge Hill University, Liverpool, Ormskirk, UK. 3 Department of Biostatistics, CHU de Caen, 14000 Caen, France. 4 Department of Nutrition and Dietetics, Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Geneva, Switzerland. 5 Bureau d'Echange des Savoirs pour des pratiques Exemplaires de Soins (BEST): A JBI Centre of Excellence, Lausanne, Switzerland. 6 Pediatric Intensive Care, HUDEF, Brussels, Belgium. 7 Pediatric Intensive Care, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. 8 University Hospital Southampton NHS Foundation Trust, Southampton, UK. 9 Pediatric Intensive Care, Pediatric Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia. 10 Pediatric Intensive Care, Assistance Publique Hôpitaux de Marseille, Marseille, France. 11 Pediatric Intensive Care, Bambino Gesù Children's Hospital, Rome, Italy. 12 Pediatric Intensive Care, S. Orosa-Malpighi University Hospital, Bologna, Italy. 13 Pediatric Intensive Care, Hospices Civils de Lyon, Lyon, France. 14 Pediatric Intensive Care, Medical School, University Hospital, University of Cete, Heraklion, Greece. 15 Moi Teaching and Referral Hospital, Eldoret, Kenya. 16 Department of Paediatrics, Division of Paediatric Critical Care Medicine, Beatrix Children's Hospital, Critical Care, Anaesthesiology, Peri-Operative and Emergency Medicine (CAPE), University of Groningen, Groningen, the Netherlands. 17 Department of Intensive Care and Neonatology, and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. 18 Pediatric Intensive Care, Gregorio Marañón General University Hospital, Madrid, Spain. 19 Pediatric Intensive Care, Alder Hey Childrens Hospital, Liverpool, UK. 20 Pediatric Intensive Care, University Hospital of Geneva, Geneva, Switzerland. 21 Department of Paediatric Anaesthesiology and Intensive Therapy, Medical University of Warsaw, Warsaw, Poland. 22 Pediatric Intensive Care, University Hospital Southampton NHS Foundation Trust, Southampton, UK. 23 Department of Pediatric Nephrology, CHU de Nantes, Nantes, France. 24 Pediatric Intensive Care, Department of Pediatrics, Faculdade de Medicina, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Universidade de Lisboa, Lisbon, Portugal. 25 Department of Intensive Care and Neonatology, and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. 26 Pediatric Intensive Care, Dr. Burhan Nalbantoglu State Hospital, Nicosia, North Cyprus, Cyprus. 27 Pediatric Intensive Care, Aglaia Kyriakou Children's Hospital, Athens, Greece. 28 Department of Biostatistics, CHU de Caen, Université Caen Normandie, INSERM U1311 DYNAMICURE, 14000 Caen, France. 29 Department of Pharmacy, CHU de Caen, Caen, France. 30 Service de Réanimation Pédiatrique, Hôpital Femme Mère Enfant, 59 Boulevard Pinel, 69500 Bron, France.

Acknowledgements

Authors would like to gratefully thank Mrs Florence Bouriot (Documentation centrale—Hospices Civils de Lyon—France), who helped as an academic librarian to build the search equations, to search the databases, to exclude the duplicates and to get the full papers.

Author contributions

FV, DB and LT initiated and led the project. All authors contributed substantially to the conception and design of the study. CJC helped as a methodologist to design the study and present the results. ARB and J-JP performed the meta-analyses. FV, DB, LT, SV, CJC, CM, LM and SR led the PICO groups. All authors contributed to the acquisition of data, or the analysis and interpretation of the data. DB, FV and LT drafted the manuscript. All authors provided critical revision of the article and provided final approval of the version submitted for publication.

Funding

No funding was received for the conduct of the review.
36. Castilla J, Carapeto I, Gutierrez R et al (2019) Efficacy and safety of isotonic saline serum as a maintenance therapy serum after general surgery in pediatrics patients. Acta Pediatr Esp 77:181–187
37. Choong K, Aroa S, Cheng J et al (2011) Hypotonic versus isotonic maintenance fluids after surgery for children: a randomized controlled trial. Pediatrics 128:857–866
38. Flores Robles CM, Cuello García CA (2016) A prospective trial comparing isotonic with hypotonic maintenance fluids for prevention of hospital-acquired hyponatremia. Paediatr Int Child Health 36:168–174
39. Friedman JN, Beck CE, DeCrooet J et al (2015) Comparison of isotonic and hypotonic intravenous maintenance fluids: a randomized clinical trial. JAMA Pediatr 169:445–451
40. Kannan L, Lodha R, Vivekanandan S et al (2010) Intravenous fluid regimens and hyponatremia among children: a randomized controlled trial. Pediatr Nephrol 25:2303–2309
41. Kumar M, Mitra K, Jain R (2020) Isotonic versus hypotonic saline as maintenance intravenous fluid therapy in children under 5 years of age admitted to general paediatric wards: a randomised controlled trial. Paediatr Int Child Health 40:44–49
42. Montañana PA, Modesto i Alapont V, Ocón AP, et al (2008) The use of isotonic fluid as maintenance therapy prevents iatrogenic hyponatremia in pediatrics: a randomized, controlled open study. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc 9:595–597
43. Perdere H-K, Dutta AK, Sodani R, Mishra K (2015) Hypotonic maintenance fluid reduces hospital acquired hyponatremia in young children with central nervous system infections. Indian J Pediatr 82:13–18
44. Ramanathan S, Kumar P, Mishra K, Dutta AK (2016) Isotonic versus hypotonic parenteral maintenance fluids: in very severe pneumonia. Indian J Pediatr 83:27–30
45. Rey C, Los-Arcos M, Hernández A et al (1992) (2011) Hypotonic versus isotonic maintenance fluids in critically ill children: a multicenter prospective randomized study. Acta Paediatr Oslo Nor 100:1138–1143
46. Saba TG, Fairbairn J, Houghton F et al (2011) A randomized controlled trial of isotonic versus hypotonic maintenance intravenous fluids in hospitalised children. BMC Pediatr 11:82
47. Torres SJ, Iolster T, Schnitzler EJ et al (2019) Hypotonic and isotonic intravenous maintenance fluids in hospitalised paediatric patients: a randomised controlled trial. BMJ Paediatr Open 3:e000385
48. Jorro Barón FA, Meregalli CN, Rombolá VA et al (2013) Hypotonic versus isotonic maintenance fluids in critically ill pediatric patients: a randomized controlled trial. Arch Argent Pediatr 111:281–287
49. Tuzun F, Akcura Y, Duman N, Ozkam H (2020) Comparison of isotonic and hypotonic intravenous fluids in term newborns: is it time to quit hypotonic fluids. J Matern Neonatal Med 35:356–361
50. Velasco P, Alcaraz Romero AJ, Oikonomopoulou N et al (2018) Hospital-acquired hyponatremia: does the type of fluid therapy affect children admitted to intensive care? [Hidronatremia adquirida en el hospital: ¿Influye el tipo de fluidoterapia en los niños ingresados a cuidados intensivos?]. Rev Chil Pediatr 89:42–49
51. Da Silva Valadão MC, Piva JP, Santana JCB, Garcia PCR (2015) Comparison of two maintenance electrolyte solutions in children in the postoperative appendectomy period: a randomized, controlled trial. J Pediatr (Rio J) 91:428–434
52. Carandang F, Angliceray A, Longhurst CA et al (2013) Association between maintenance fluid tonicity and hospital-acquired hyponatremia. J Pediatr 163:1646–1651. https://doi.org/10.1016/j.jpeds.2013.07.020
53. Gollshaken K, Badel H, Min M et al (2016) Suitable intravenous fluid for preventing dysnatremia in children with gastroenteritis; a randomized clinical trial. J Ren hkmj2 09010
54. Karageorgos S, Kratimenos P, Landicho A et al (2018) Hospital-acquired hyponatremia in children following hypotonic versus isotonic intravenous fluids infusion. Children S139. https://doi.org/10.3390/childrens100139
55. Lima MF, Neville IS, Cavalheiro S et al (2019) Balanced crystalloids versus saline for perioperative intravenous fluid administration in children undergoing neurosurgery: a randomized clinical trial. J Neurosurg Anesthesiol 31:30–35
56. Naseem M, Dubey AP, Mishra TK, Singh R (2020) Effect of rehydration with normal saline versus ringer lactate on serum sodium level of children with acute diarrhea and severe dehydration: a randomized controlled trial. Indian Pediatr 57:519–522
57. Mahajan V, Sajan SS, Sharma A, Kaur J (2012) Ringers lactate vs Normal saline for children with acute diarrhea and severe dehydration—a double blind randomized controlled trial. Indian Pediatr 49:963–968
58. Kartha GB, RameshKumar R, Mahadevan S (2017) Randomized double-blind trial of ringer lactate versus normal saline in pediatric acute severe diarrheal dehydration. J Pediatr Gastroenterol Nutr 65:621–626
59. Gutman RA, Drutz DJ, Whalen GE, Watten RH (1969) Double blind fluid therapy evaluation in pediatric cholera. Pediatrics 44:922–931
60. Farrell PR, Farrell LM, Hormung L, Abu-El-Hajai M (2020) Use of lactated ringers solution compared with normal saline is associated with shorter length of stay in pediatric acute pancreatitis. Pancreas 49:375–380
61. Yung M, Letton G, Keeley S (2017) Controlled trial of Hartmann’s solution versus 0.9% saline for diabetic ketoacidosis. J Paediatr Child Health 53:12–17
62. Williams V, Jayashree M, Nallasamy K et al (2020) 0.9% saline versus plasma-lyte as initial fluid in children with diabetic ketoacidosis (SIPInk trial): a double-blind randomized controlled trial. Crit Care Lond Engl. https://doi.org/10.1186/s13054-019-2683-3
63. Balamuth F, Kittick M, McBride P et al (2019) Pragmatic Pediatric Trial of balanced versus normal saline fluid in sepsis: the PRoMPT BOLUS randomised controlled trial pilot feasibility study. Acad Emerg Med Off J Soc Acad Emerg Med 26:1346–1356. https://doi.org/10.1111/ace.13815
64. Bulfon AF, Alomani HL, Anton N et al (2019) Intravenous fluid prescription practices in critically ill children: a shift in focus from natrexia to chloremia? J Pediatr Intensive Care 8:218–225. https://doi.org/10.1055/s-0039-1692413
65. Martinez Carapeto I, López Castilla JD (2003) Fresnedas Gutiérrez R (2018) [A comparison of post-surgical plasma glucose levels in patients on fluids with different glucose concentrations]. An Pediatr Barc Spain 89:98–103
66. de Betue CTI, Verbruggen SCAT, Schierbeek H et al (2012) Does a reduced glucose intake prevent hyperglycemia in children early after cardiac surgery? a randomized controlled crossover study. Crit Care Lond Engl 16:R176. https://doi.org/10.1186/cc11658
67. Verbruggen SCAT, de Betue CTI, Schierbeek H et al (2011) Reducing glucose infusion safely prevents hyperglycemia in post-surgical children. Clin Nutr Edinb Scotl 30:786–792. https://doi.org/10.1016/j.clnu.2011.05.011
68. Lex D, Szántó P, Breuer T et al (2014) Impact of the insulin and glucose content of the postoperative fluid on the outcome after pediatric cardiac surgery. Interv Med Appl Sci 6:160–169
69. Diaz F, Nuhez MJ, Pino P et al (2018) Implementation of preemptive fluid strategy as a bundle to prevent fluid overload in children with acute respiratory distress syndrome and sepsis. BMC Pediatr. https://doi.org/10.1186/s12877-018-1188-6
70. Ingelise SA, Geukers VG, Desselhoff ME et al (2019) Less is more?—a feasibility study of fluid strategy in critically ill children with acute respiratory tract infection. Front Pediatr 7:496. https://doi.org/10.3389/fped.2019.00496
71. Yuan M, Keeley S (2009) Randomised controlled trial of intravenous maintenance fluids. J Paediatr Child Health 45:9–14
72. Raksha SK, Dakshayani B, Premalatha R (2017) Full volume isotonic (0.9%) vs. two-thirds volume hypotonic (0.18%) intravenous maintenance fluids in preventing hyponatremia in children admitted to pediatric intensive care unit—a randomized controlled study. J Trop Pediatr 63:454–460
73. Neville KA, Sandeman DJ, Rubinstein A et al (2010) Prevention of hyponatremia during maintenance intravenous fluid administration: a prospective randomised study of fluid type versus fluid rate. J Pediatr 156:313–319 e1-2
74. Singh SC, Singh PD, Sinivas B et al (1995) Fluid restriction does not improve the outcome of acute meningitis. Pediatr Infect Dis J 14:495–503
75. Leung LC, So L, Ng Y et al (2021) Initial intravenous fluid prescription in general paediatric in-patients aged >28 days and <18 years: consensus statements. Hong Kong Med J 27:276–286. https://doi.org/10.12809/hkmj209010